These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 12729388)

  • 21. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.
    Turner EH; Knoepflmacher D; Shapley L
    PLoS Med; 2012; 9(3):e1001189. PubMed ID: 22448149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should we treat depression with drugs or psychological interventions? A reply to Ioannidis.
    Davis JM; Giakas WJ; Qu J; Prasad P; Leucht S
    Philos Ethics Humanit Med; 2011 May; 6():8. PubMed ID: 21569244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylphenidate for fatigue in ambulatory men with prostate cancer.
    Roth AJ; Nelson C; Rosenfeld B; Scher H; Slovin S; Morris M; O'Shea N; Arauz G; Breitbart W
    Cancer; 2010 Nov; 116(21):5102-10. PubMed ID: 20665492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity analysis of informatively coarsened data using pattern mixture models.
    Shardell M; El-Kamary SS
    J Biopharm Stat; 2009 Nov; 19(6):1018-38. PubMed ID: 20183462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.
    Molnar FJ; Man-Son-Hing M; Hutton B; Fergusson DA
    Open Med; 2009 Mar; 3(2):e31-50. PubMed ID: 19946392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Side effects from the copper IUD: do they decrease over time?
    Hubacher D; Chen PL; Park S
    Contraception; 2009 May; 79(5):356-62. PubMed ID: 19341847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cognitive training program based on principles of brain plasticity: results from the Improvement in Memory with Plasticity-based Adaptive Cognitive Training (IMPACT) study.
    Smith GE; Housen P; Yaffe K; Ruff R; Kennison RF; Mahncke HW; Zelinski EM
    J Am Geriatr Soc; 2009 Apr; 57(4):594-603. PubMed ID: 19220558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does analysis using "last observation carried forward" introduce bias in dementia research?
    Molnar FJ; Hutton B; Fergusson D
    CMAJ; 2008 Oct; 179(8):751-3. PubMed ID: 18838445
    [No Abstract]   [Full Text] [Related]  

  • 29. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression.
    Tadić A; Rujescu D; Müller MJ; Kohnen R; Stassen HH; Szegedi A; Dahmen N
    Neuropsychiatr Dis Treat; 2008 Feb; 4(1):269-76. PubMed ID: 18728809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials.
    Prakash A; Risser RC; Mallinckrodt CH
    Int J Clin Pract; 2008 Aug; 62(8):1147-58. PubMed ID: 18564199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analytical approaches to reporting long-term clinical trial data.
    Papp KA; Fonjallaz P; Casset-Semanaz F; Krueger JG; Wittkowski KM
    Curr Med Res Opin; 2008 Jul; 24(7):2001-8. PubMed ID: 18534049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Handling missing quality of life data in HIV clinical trials: what is practical?
    Fairclough DL; Thijs H; Huang IC; Finnern HW; Wu AW
    Qual Life Res; 2008 Feb; 17(1):61-73. PubMed ID: 18071926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine in the treatment of major depressive disorder: an open-label study.
    Hudson JI; Perahia DG; Gilaberte I; Wang F; Watkin JG; Detke MJ
    BMC Psychiatry; 2007 Aug; 7():43. PubMed ID: 17725843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
    Holford NH; Chan PL; Nutt JG; Kieburtz K; Shoulson I;
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):281-311. PubMed ID: 16625427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.
    Mallinckrodt CH; Raskin J; Wohlreich MM; Watkin JG; Detke MJ
    BMC Psychiatry; 2004 Sep; 4():26. PubMed ID: 15355546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations.
    Mallinckrodt CH; Clark SW; Carroll RJ; Molenbergh G
    J Biopharm Stat; 2003 May; 13(2):179-90. PubMed ID: 12729388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.
    Siddiqui O; Hung HM; O'Neill R
    J Biopharm Stat; 2009; 19(2):227-46. PubMed ID: 19212876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA.
    Mallinckrodt CH; Kaiser CJ; Watkin JG; Molenberghs G; Carroll RJ
    Clin Trials; 2004; 1(6):477-89. PubMed ID: 16279288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MMRM versus MI in dealing with missing data--a comparison based on 25 NDA data sets.
    Siddiqui O
    J Biopharm Stat; 2011 May; 21(3):423-36. PubMed ID: 21442517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of practical approaches for handling missing data in clinical trials.
    DeSouza CM; Legedza AT; Sankoh AJ
    J Biopharm Stat; 2009 Nov; 19(6):1055-73. PubMed ID: 20183464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.